REG - IXICO plc - Exercise of Options & Director/PDMR Purchase

IXICOAnnouncement

10/10/2024 13:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241010:nRSJ7476Ha&default-theme=true

RNS Number : 7476H  IXICO plc  10 October 2024

10 October 2024

 

 

IXICO plc

("IXICO" or the "Company")

 

Exercise of Options & Director/PDMR Purchase

 

 

IXICO plc (AIM: IXI), the medical imaging advanced analytics company
delivering insights in neuroscience, announces that it has issued, conditional
on admission, 1,695,717 new ordinary shares of 1 pence each in the capital of
the Company ("Ordinary Shares"), pursuant to the exercise of share options
("Options") under the Company's 2014 EMI Share Option Plan (the "2014 Plan").
200,000 of these Options were exercised by Grant Nash, Chief Financial Officer
and PDMR of the Company.

 

All tax and costs were paid separately by Mr Nash with no sale of Ordinary
Shares required.  Following this exercise, Mr Nash's holding has increased to
400,000 Ordinary Shares representing approximately 0.8% of the current Issued
Share Capital of the Company.

 

In addition, Mark Warne, Chair of the Company has purchased 52,685 Ordinary
Shares in the market.  Following this purchase, Mr Warne's holding has
increased to 72,335 representing approximately 0.14% of the current Issued
Share Capital of the Company.

 

The new Ordinary Shares will rank pari passu with the existing Ordinary Shares
in issue and application has been made for the new Ordinary Shares to be
admitted to trading on the AIM Market of the London Stock Exchange
("Admission"). Admission is expected to occur, and dealings in the new
Ordinary Shares commence, at 8:00 a.m. on 14 October 2024.

 

Total Voting Rights

 

Following Admission, the Company will have 50,047,090 Ordinary Shares in
issue. This figure of 50,047,090 may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change of their interest in, the
Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

For further information please contact:

 

 IXICO plc                                                               +44 (0) 20 3763 7499
 Bram Goorden, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cavendish Capital Markets Limited                                       +44 (0) 20 7220 0500

 (Nominated adviser and sole broker)
 Giles Balleny / Dan Hodkinson (Corporate Finance)
 Nigel Birks (Life Sciences Specialist Sales)

 Harriet Ward (Corporate Broking)

 Michael F Johnson / Tamar Cranford Smith (Sales)

 

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.IXICO.com) and
follow us on Twitter @IXICOnews

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.

 

 1      Details of the person discharging managerial responsibilities/person closely
        associated
 a)     Name                                                         Grant Nash
 2      Reason for the notification
 a)     Position/status                                              Chief Financial Officer and PDMR
 b)     Initial notification /Amendment                              Initial notification
 3      Details of the issuer, emission allowance market participant, auction
        platform, auctioneer or auction monitor
 a)     Name                                                         IXICO plc

 b)     LEI                                                          2138005M1F59O6HWSA97

 4      Details of the transaction(s): section to be repeated for (i) each type of

      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
        place where transactions have been conducted
 a)     Description of the financial instrument, type of instrument  Ordinary shares in IXICO plc

        Identification code

                                                                     ISIN: GB00BFXR4C20
 b)     Nature of the transaction                                    Exercise of Options

 c)     Price(s) and volume(s)                                        Price(s)   Volume(s)
                                                                     1pence     200,000
 d)     Aggregated information

         - Aggregated volume                                         N/A

         - Price
 e)     Date of the transaction                                      9 October 2024

 f)     Place of the transaction                                     Outside of a trading venue

d)

Aggregated information

 - Aggregated volume

 - Price

 

N/A

 

e)

 

Date of the transaction

9 October 2024

 

f)

 

Place of the transaction

Outside of a trading venue

 

 

 1      Details of the person discharging managerial responsibilities/person closely
        associated
 a)     Name                                                         Mark Warne
 2      Reason for the notification
 a)     Position/status                                              Chair and PDMR
 b)     Initial notification /Amendment                              Initial notification
 3      Details of the issuer, emission allowance market participant, auction
        platform, auctioneer or auction monitor
 a)     Name                                                         IXICO plc

 b)     LEI                                                          2138005M1F59O6HWSA97

 4      Details of the transaction(s): section to be repeated for (i) each type of

      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
        place where transactions have been conducted
 a)     Description of the financial instrument, type of instrument  Ordinary shares in IXICO plc

        Identification code

                                                                     ISIN: GB00BFXR4C20
 b)     Nature of the transaction                                    Purchase of Ordinary Shares

 c)     Price(s) and volume(s)                                        Price(s)    Volume(s)
                                                                     9.5 pence    26,315

9.48 pence
                                                                     26,370

 d)     Aggregated information

         - Aggregated volume                                         52,685 Ordinary Shares

         - Price                                                     9.49 pence
 e)     Date of the transaction                                      9 October 2024

                                                                     10 October

 f)     Place of the transaction                                     LSE/AIMX

d)

Aggregated information

 - Aggregated volume

 - Price

 

52,685 Ordinary Shares

9.49 pence

e)

 

Date of the transaction

9 October 2024

10 October

 

f)

 

Place of the transaction

LSE/AIMX

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFFAFESELSEFS